Aristotle University Of Thessaloniki (AUTH)
Αποσιδήρωση παιδιών και εφήβων με ομόζυγη β-μεσογειακή αναιμία με νέο θεραπευτικό σχήμα: έλεγχος επίδρασης στο νευρικό και ανοσιακό σύστημα
Abstract
dc:descriptionNowadays the therapeutic management of homozygous thalassaemia includes blood transfusions and chelation therapy. Chelation therapy is being demonstrated since 1978 by the use of subcutaneous desferrioxamine. Because of this painful therapeutic procedure, a new method had to be found, which should be more usable, like the application of a chelator per os. Since 2001, deferiprone constitutes an alternative solution for patients with thalassaemia, hemosiderosis and severe toxicity, during therapy with desferrioxamine. Deferiprone is being applicated as a monotherapy or combinated with desferrioxamine. The aim of this study was the assessment of the safety of deferiprone as monotherapy or as a combination with desferioxamine in children and adolescents with homozygous thalassaemia. The effects of the chelator in the immune and the central and peripheral nervous system have been studied. The uniqueness of this study is the long term research of the immune and neural system in patients with homozygous thalassaemia, as well as the large number of the patients who participated in this study. The study of the immune system included, measurements of immunoglobulins, autoantibodies, rheumatoid factor and C-reactive protein. For the nervous system a registration of evoked potentials, nerve conduction velocities, as well as verbal performance and total IQ evaluation using the Wechsler Intelligence Scale for children (WISC-III) was undertaken. The study involved 44 patients with homozygous thalassaemia, aged 9 – 30 years (mean 19,4 ± 4.9), who were treated and followed-up in the Thalassaemia Unit of the Hippokration General Hospital in Thessaloniki. 21 patients were treated with L1 (group A) and 23 with L1 in combination with DFO (group B). All patients were free of clinically and elaborately apparent infections at the time of analysis; therefore, 20 age matched healthy volunteers were used as controls. During the first and second year of the new chelation treatment, 3 of our 44 patients stopped their chelation, 2 because of severe agranulocytosis and 1 because of chronic abdominal pain. According to the results of humoral immunity, there was no statistical difference between the two groups, concerning the mean serum immunoglobulin concentrations (IgG, IgM, IgA - p>0.5 vs. controls). Thalassaemic patients demonstrated increased Β-cell counts (CD19⁺) in both treatment groups, before and after treatment (p<0,05 vs controls). CD4⁺ and CD8⁺ counts were increased in thalassaemic patients due to lymphocytosis, although CD4⁺/CD8⁺ ratio did not significantly differ compared to controls (p>0.05), which proves that there was no immunosuppression during the study. The absolute number of T-cells (CD3⁺) was significantly high in both treatment groups compared to the control group (p<0,05) before and 2 years after the new chelation therapy, while the percentages of CD3⁺ cells did not significantly differ between the 3 groups. The assessment of the title of the antinuclear and non-organoid antibodies did not prove any differences between the two groups of chelation therapy and the control group. The results of the evoked potential control proved no pathological auditory evoked potentials (BAEP) in none of our patients. The same satisfactory results were found in the records of the visual (VEP) and the somatosensory evoked potentials (SEP), except in one of the 44 patients (2,27%) who showed a pathological SEP. Concerning the nerve conduction velocities the percentages of children and adolescents with pathological motor and sensory nerve conduction velocity were 13,63% and 13,63% respectively. None of our patients with pathological findings in their neurophysiological examination presented any sign or symptom of involvement of the nervous system. Finally, concerning the study of the neuropsychological examination, only one patient showed a low mean intelligence quotient (7,1%). In conclusion, the percentage of patients with disorders of the immune and nervous system concerned very few cases. Our two years study supports the safety of deferiprone use, regarding the immune and neural function, offering to thalassaemic patients the great advantage of a per os chelation therapy with no complications.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tourkantoni, Natalia
- Τουρκαντώνη, Ναταλία
Subjects
dc:subject × 15- Μεσογειακή αναιμία, Ομόζυγη β
- Αποσιδήρωση
- Δεφεριπρόνη
- Αποσιδήρωση, Συνδυασμένη
- Ανοσιακό σύστημα
- Νευροφυσιολογικό σύστημα
- Beta - thalassaemia
- De feriprene
- Combined chelation
- Immune system
- Neurophysiological system
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/20643